Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

18. März 2026 08:00 ET | Quelle: Amphista Therapeutics

Amphista Therapeutics appoints Louise Modis Ph.D. as CEO and Patrick Kelly M.D. as CMO and provides a business update as the Company prepares to file IND application for AMX-883

Strengthening the clinical leadership as the Company progresses to the clinic with its BRD9 Targeted Glue™, AMX-883, in acute myeloid leukemiaAmphista continues to advance its SMARCA and TEAD...
03. September 2024 07:00 ET | Quelle: Amphista Therapeutics

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue™ protein...
03. September 2024 03:00 ET | Quelle: Amphista Therapeutics

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue™ protein...